Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.
SARS-CoV-2
chemoprophylaxis
nafamostat
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
received:
05
07
2023
revised:
04
08
2023
accepted:
11
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models. Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life. This study sought to determine whether intranasal dosing of nafamostat at 5 mg/kg twice daily was able to prevent the airborne transmission of SARS-CoV-2 from infected to uninfected Syrian Golden hamsters. SARS-CoV-2 RNA was detectable in the throat swabs of the water-treated control group 4 days after cohabitation with a SARS-CoV-2 inoculated hamster. However, throat swabs from the intranasal nafamostat-treated hamsters remained SARS-CoV-2 RNA negative for the full 4 days of cohabitation. Significantly lower SARS-CoV-2 RNA concentrations were seen in the nasal turbinates of the nafamostat-treated group compared to the control (
Identifiants
pubmed: 37632086
pii: v15081744
doi: 10.3390/v15081744
pmc: PMC10458615
pii:
doi:
Substances chimiques
nafamostat
Y25LQ0H97D
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI134091
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI118397
Pays : United States
Organisme : Medical Research Council
ID : MR/W005611/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010145/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R00904X/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R018863/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N022505/1
Pays : United Kingdom
Références
Nat Commun. 2021 Sep 22;12(1):5469
pubmed: 34552091
FEBS Lett. 2021 Sep;595(18):2323-2340
pubmed: 34331769
Antimicrob Agents Chemother. 2012 Aug;56(8):4365-74
pubmed: 22664975
Viruses. 2020 Jun 10;12(6):
pubmed: 32532094
Circ Res. 2020 Jul 31;127(4):571-587
pubmed: 32586214
Br J Cancer. 2006 Oct 23;95(8):1056-61
pubmed: 17003781
Vet Clin North Am Exot Anim Pract. 2011 May;14(2):287-337, vi
pubmed: 21601816
Clin Infect Dis. 2020 Nov 19;71(16):2139-2149
pubmed: 32472679
Int J Infect Dis. 2021 Jan;102:529-531
pubmed: 33157292
Viruses. 2021 May 28;13(6):
pubmed: 34071726
mBio. 2021 Aug 31;12(4):e0097021
pubmed: 34340553
Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2
pubmed: 33789085
Protein Cell. 2022 Jan;13(1):72-77
pubmed: 34491552
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
ACS Chem Biol. 2014 Aug 15;9(8):1869-76
pubmed: 24918547
Emerg Microbes Infect. 2022 Dec;11(1):277-283
pubmed: 34951565
Clin Pharmacol Ther. 2015 May;97(5):518-25
pubmed: 25676789
Nat Commun. 2023 May 11;14(1):2671
pubmed: 37169744
Eur J Med Chem. 2023 Sep 5;257:115503
pubmed: 37229831
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Nat Commun. 2023 Jun 5;14(1):3267
pubmed: 37277327
J Aerosol Med Pulm Drug Deliv. 2008 Mar;21(1):113-24
pubmed: 18518837
J Virol. 2019 Mar 5;93(6):
pubmed: 30626688
Virology. 2018 Apr;517:9-15
pubmed: 29217279
Antimicrob Agents Chemother. 2015 Mar;59(3):1549-57
pubmed: 25534741
Viruses. 2021 Jul 27;13(8):
pubmed: 34452325
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Am J Pathol. 2022 Feb;192(2):195-207
pubmed: 34767812